9T0H

NCS-1 bound to a FDA-approved drug

Summary for 9T0H

• Entry DOI: 10.2210/pdb9t0h/pdb
• Descriptor: Neuronal calcium sensor 1, CALCIUM ION, DI(HYDROXYETHYL)ETHER, ... (8 entities in total)
• Functional Keywords: complex, modulator, metal binding protein
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 21006.73

Authors

Miro-Rodriguez, C.,Sanchez-Barrena, M.J. (deposition date: 2025-10-17, release date: 2026-03-11, Last modification date: 2026-03-18)

Primary citation

Gonzalez-Garcia, E.,Miro-Rodriguez, C.,Ulzurrun, E.,Toledano, O.,Perez-Suarez, S.,Aguado, L.,Sanchez-Barrena, M.J.,Mansilla, A.,Naveiro, R.,Campillo, N.E.
An AI-based approach accelerates the discovery of protein-protein interaction modulators targeting NCS-1.
Eur.J.Med.Chem., 309:118739-118739, 2026

PubMed Abstract: Drug repurposing is an efficient strategy to accelerate the identification of therapeutic compounds by finding new uses for existing drugs. Here, we leveraged artificial intelligence (AI) to optimize this process and discover protein-protein interaction (PPI) modulators targeting the Neuronal Calcium Sensor 1. AI models were trained on large datasets of known PPIs, protein structures, and small molecular graphs to predict binding score. Using virtual screening of an FDA-approved drug library, the models generated a prioritized list of candidates. The most promising compounds were selected for experimental validation. This integrated approach efficiently reduced experimental workload, time, and cost, leading to the identification of dipyridamole as a selective modulator of the interaction between NCS-1 and the dopamine D receptor. The crystal structure of NCS-1 in complex with dipyridamole elucidates its mechanism of modulation. Our findings highlight the potential of AI to streamline and accelerate the discovery of novel therapeutic PPI modulators.

PubMed: 41785832
DOI: 10.1016/j.ejmech.2026.118739

Experimental method

X-RAY DIFFRACTION (1.91 Å)